DETAILED ACTION
1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
2. Response to Election/Restriction filed on 3/30/2026 is acknowledged.
3. Claim filed on 8/18/2023 is acknowledged.
4. Claims 13, 18 and 19 have been cancelled.
5. New claims 20-23 have been added.
6. Claims 1-12, 14-17 and 20-23 are pending in this application.
7. Claims 14-17 and 20-23 are withdrawn from consideration pursuant to 37 CFR 1.142(b), as being drawn to non-elected inventions, there being no allowable generic or linking claim.
8. Claims 1-12 are under examination.
Priority
9. The application is a 371 of PCT/EP2022/054063 filed on 2/18/2022, which claims foreign priority to EP 21158189.7 filed on 2/19/2021 and EP 21187173.6 filed on 7/22/2021. The filing date of the priority documents has been perfected. Furthermore, EP 21158189.7 provides support to instant claims 1-12. Therefore, the effective filing date of instant claims 1-12 is 2/19/2021.
Elections/Restrictions
10. Applicant’s election of Group 1 (claims 1-12) and election of compound D22 with the structure
PNG
media_image1.png
406
666
media_image1.png
Greyscale
as species of compound of formula (I) or a salt thereof in the reply filed on 3/30/2026 is acknowledged. Applicant fails to explicilty state whether the election is made with traverse or not. However, Applicant made the comments that multiple groups can be searched and examined together without undue burden. In the instant case, the Examiner would like to point out that for US 371 of PCT application, the restriction is based on whether there is a unity of invention or not, and it is not based on whether there is undue burden or not. Therefore, the requirement is made FINAL in this office action.
Group 1 is drawn to compound of formula (I) or a salt thereof:
PNG
media_image2.png
332
646
media_image2.png
Greyscale
; and pharmaceutical composition comprising such compound or a salt thereof and optionally i) one or more carrier substances and/or ii) one or more adjuvants and/or iii) one or more further active pharmaceutical ingredient(s). A search was conducted on the elected species; and this appears to be free of prior art. A search was extended to the genus in claim 1; and this too appears to be free of prior art. Claims 1-12 are examined on the merits in this office action.
Objections
11. The specification is objected to for the following minor informality: The instant specification discloses various peptides and nucleic acid sequences throughout the specification. However, they are missing the sequence identifier. Applicant is required to amend the specification to comply with 37 CFR 1.821(d).
Please note: The specification has not been checked to the extent necessary to determine the presence of all possible error. Applicant's cooperation is required in correcting any errors of which applicant may become aware in the specification (see MPEP § 608.01).
12. The drawings are objected to for the following minor informality:
Figure 2 discloses amino acid and DNA sequences. However, they are missing the sequence identifier. Applicant is required to amend Figure 2 to comply with 37 CFR 1.821(d).
Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.
13. Claim 1 is objected to for the following minor informality: First, Applicant is suggest to add a comma after each of the recited chemical formulae. Second, Applicant is suggested to amend claim 1 as "A compound of formula (I) or a salt thereof:
PNG
media_image2.png
332
646
media_image2.png
Greyscale
, wherein: R1, R2, and R4 are independently selected from H, -CH3, -CH2OH; one of the following groups:…
PNG
media_image3.png
86
110
media_image3.png
Greyscale
; -CH2-SR1A, wherein R1A is selected from an alkyl, an alkenyl, an alkynyl, a heteroalkyl, a cycloalkyl, a heterocycloalkyl, an alkylcycloalkyl, a heteroalkylcycloalkyl, an aryl, a heteroaryl, an aralkyl or a heteroaralkyl group, and wherein all these groups are optionally substituted; or -CH2-Ind, wherein Ind is an optionally substituted indole group; R3 is selected from H, -OH, -SH, -COOH, -CONH2; one of the following groups:…
PNG
media_image4.png
96
118
media_image4.png
Greyscale
; -SR3A, wherein R3A is selected from an alkyl, an alkenyl, an alkynyl, a heteroalkyl, a cycloalkyl, a heterocycloalkyl, an alkylcycloalkyl, a heteroalkylcycloalkyl, an aryl, a heteroaryl, an aralkyl or a heteroaralkyl group, and wherein all these groups are optionally substituted; or -Ind, wherein Ind is an optionally substituted indole group; R5 is -CH2-Ind, wherein Ind is an optionally substituted indole group…R8 is independently selected from…R8A is independently selected from…”.
14. Claim 2 is objected to for the following minor informality: Applicant is suggested to amend claim 2 as “…wherein -CH2-Ind is
PNG
media_image5.png
192
254
media_image5.png
Greyscale
; and wherein R9 is…R11 is independently selected from…; and n is…”.
15. Claim 3 is objected to for the following minor informality: Applicant is suggested to amend claim 3 as “…wherein -CH2-SR1A is
PNG
media_image6.png
186
218
media_image6.png
Greyscale
”.
16. Claim 4 is objected to for the following minor informality: Applicant is suggested to amend claim 4 as “…wherein R1 is selected from the group consisting of…”.
17. Claim 5 is objected to for the following minor informality: First, Applicant is suggest to add a comma after each of the recited chemical formula. Second, Applicant is suggested to amend claim 5 as “…wherein R2 is selected from the group consisting of -CH2-OH, -CH2-CH(CH3)-OH, -CH3,
PNG
media_image7.png
122
208
media_image7.png
Greyscale
,…and
PNG
media_image8.png
88
98
media_image8.png
Greyscale
”.
18. Claim 6 is objected to for the following minor informality: Applicant is suggested to amend claim 6 as “…wherein R3 is selected from the group consisting of a hydrogen atom, -CH2-CH2-CH2-NH2 and…”.
19. Claim 7 is objected to for the following minor informality: First, Applicant is suggest to add a comma after each of the recited chemical formula. Second, Applicant is suggested to amend claim 7 as “…wherein R4 is selected from the group consisting of -CH2-OH,…and
PNG
media_image9.png
84
102
media_image9.png
Greyscale
; or R4 is -CH2-SR4A, wherein R4A is selected from an alkyl, an alkenyl, an alkynyl, a heteroalkyl, a cycloalkyl, a heterocycloalkyl, an alkylcycloalkyl, a heteroalkylcycloalkyl, an aryl, a heteroaryl, an aralkyl or a heteroaralkyl group, and wherein all these groups are optionally substituted”.
20. Claim 8 is objected to for the following minor informality: Applicant is suggested to amend claim 8 as “…wherein R5 is
PNG
media_image5.png
192
254
media_image5.png
Greyscale
; and wherein R9 is…R11 is independently selected from; and n is…”.
21. Claim 11 is objected to for the following minor informality: Applicant is suggested to amend claim 11 as “The compound or a salt thereof according to claim 1, wherein the compound is formula (Ia):
PNG
media_image10.png
366
688
media_image10.png
Greyscale
; and wherein R1…are defined as in claim 1”.
22. Claim 12 is objected to for the following minor informality: Applicant is suggested to amend claim 12 as “A pharmaceutical composition comprising a compound or a salt thereof according to claim 1; and optionally i) one or more carrier substances, and/or ii) one or more adjuvants, and/or iii) one or more additional active pharmaceutical ingredient(s)”.
Rejections
Claim Rejections - 35 U.S.C. § 112 paragraph (b)
23. The following is a quotation of 35 U.S.C. 112(b):
(B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
24. Claims 1-12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention.
25. Claim 1 recites the limitations “(especially a hydrogen atom)” and “(especially 0 or 1; preferably 0)”. First, the metes and bounds of claim 1 is rendered vague and indefinite by the parenthetical recitations of “(especially a hydrogen atom)” and “(especially 0 or 1; preferably 0)” because it is unclear as to whether the limitations are part of the instantly claimed subject matter. Second, the terms “preferably” and “especially” render the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention (see MPEP § 2173.05(d)).). Taken all these together, the metes and bounds of instant claim 1 is vague and indefinite. Because claims 2-12 depend from indefinite claim 1 and none of the dependent claims clarifies the point of confusion, they must also be rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph.
26. Similar to the rejection set forth in Section 25 above, the metes and bounds of claims 2, 4-8 and 10 are rendered vague and indefinite by both the parenthetical recitations and the terms “preferably” and/or “especially”.
27. Claim 11 recites the limitation “…wherein R1…m and p are as defined in any one of the preceding claims”. Such recitation includes both broad limitation (claim 1) and narrow limitation (claims 2-10). Therefore, the metes and bounds of instant claim 11 are vague and indefinite.
Claim Rejections - 35 U.S.C. § 112 paragraph (d)
28. The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), fourth paragraph:
Subject to the [fifth paragraph of 35 U.S.C. 112 (pre-AIA )], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
29. Claims 4 and 5 are rejected under 35 U.S.C. 112(d) or 35 U.S.C. 112 (pre-AIA ), 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
30. Claim 4 depends on claim 1; and claim 4 recites “The compound or a salt thereof according to claim 1, wherein R1 is selected from…and -CH2-CH(CH3)-OH”. However, R1 recited in instant claim 1 cannot be -CH2-CH(CH3)-OH. Therefore, the scope of the compound or a salt thereof recited in instant claim 4 is broader than that of the compound or a salt thereof recited in instant claim 1. Claim 4 does not further limit the compound or a salt thereof in claim 1; therefore, claim 4 is improper dependent forms for failing to further limit the subject matter of claim 1.
31. Claim 5 depends on claim 1; and claim 5 recites “The compound or a salt thereof according to claim 1, wherein R2 is selected from…-CH2-CH(CH3)-OH…”. However, R2 recited in instant claim 1 cannot be -CH2-CH(CH3)-OH. Therefore, the scope of the compound or a salt thereof recited in instant claim 5 is broader than that of the compound or a salt thereof recited in instant claim 1. Claim 5 does not further limit the compound or a salt thereof in claim 1; therefore, claim 5 is improper dependent forms for failing to further limit the subject matter of claim 1.
Examiner’s Notes
32. The compound of formula (I) or a salt thereof:
PNG
media_image2.png
332
646
media_image2.png
Greyscale
, and pharmaceutical composition comprising such compound or a salt thereof recited in instant claims 1-12 are free of prior art. The closest prior art is Schäberle et al (WO 2021/098989 A1, filed with IDS). Schäberle et al, throughout the patent, teach bicyclic heptapeptide of general formula I, including formulae III-XVIII and IXX-XXII, for example, page 4, lines 1-5; Figures 6-9, 11 and 12; and claim 1. However, there is no teaching, motivation, or other type of suggestion to either select (1H-indol-3-yl)-methyl or halogenated (1 H-indol-3-yl)-methyl from the Markush group of R4, and/or modify the R4 position in the compounds of formulae III-XVIII and IXX-XXII in Schäberle et al and arrive at the compound of formula (I) or a salt thereof and pharmaceutical composition comprising such compound or a salt thereof recited in instant claims 1-12. Therefore, the compound of formula (I) or a salt thereof and pharmaceutical composition comprising such compound or a salt thereof recited in instant claims 1-12 are both novel and unobvious over the prior arts of record. And the claimed compound of formula (I) or a salt thereof and pharmaceutical composition comprising such compound or a salt thereof recited in instant claims 1-12 are markedly different from what exist in nature.
Conclusion
No claim is allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to LI N KOMATSU whose telephone number is (571)270-3534. The examiner can normally be reached Mon-Fri 8am-4pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached on 5712707430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/LI N KOMATSU/Primary Examiner, Art Unit 1658